Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Rhea-AI Summary
Mereo BioPharma (NASDAQ:MREO) reported second quarter 2026 results and corporate updates. The company entered an option and license agreement with Sentynl Therapeutics for alvelestat in AATD‑LD, under which it would be eligible, upon option exercise, to receive $40 million in upfront and R&D payments, up to $435 million in milestones and double‑digit tiered U.S. royalties, while retaining rest‑of‑world commercial rights and leading a funded global Phase 3 trial potentially starting in early 2027.
With partner Ultragenyx, Mereo is in regulatory discussions in the U.S. and U.K. on the path forward for setrusumab in osteogenesis imperfecta after Phase 3 studies that did not meet primary fracture endpoints but showed statistically significant gains in bone mineral density and other measures. Q2 2026 R&D expenses fell to $1.8 million from $5.4 million, G&A to $5.2 million from $5.5 million, and net loss narrowed to $7.0 million from $14.6 million. Cash and cash equivalents were $30.1 million, expected to fund operations into late‑2027. Total assets were $34.7 million and shareholders’ equity $28.7 million at June 30, 2026.
Positive
- Net loss halved to $7.0 million from $14.6 million YoY in Q2 2026
- R&D expenses cut to $1.8 million from $5.4 million YoY in Q2 2026
- Cash runway extended to late‑2027 on $30.1 million cash at June 30, 2026
- Alvelestat deal with Sentynl includes $40 million potential upfront/R&D and up to $435 million in milestones
- Setrusumab Phase 3 showed statistically significant bone mineral density improvements and favorable safety profile
Negative
- Phase 3 setrusumab trials did not achieve statistical significance on primary fracture endpoints
- Cash balance declined to $30.1 million from $41.0 million since December 31, 2025
- No revenue recognized in Q2 2026 compared to $0.5 million in Q2 2025
- Shareholders’ equity fell to $28.7 million from $40.9 million at year‑end 2025
Market reaction after 2Q26 earnings report: MREO +25.04%
Following this news, MREO has gained 25.04%, reflecting a significant positive market reaction. Argus tracked a peak move of +28.4% during the session. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner has triggered 70 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $0.34. Trading volume is exceptionally heavy at 29316.1x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | 1Q26 earnings | Positive | +1.4% | Narrower net loss, cash runway, and pipeline updates supported the quarterly release. |
| Mar 19 | FY25 earnings | Positive | +2.6% | Cash runway and secondary setrusumab results accompanied annual financial reporting. |
| Nov 10 | 3Q25 earnings | Positive | +5.7% | Pipeline catalysts and partnering discussions accompanied third-quarter financial results. |
| Aug 12 | 2Q25 earnings | Positive | +9.2% | Cash position and setrusumab Phase 3 progress accompanied quarterly results. |
| May 13 | 1Q25 earnings | Negative | -7.2% | Pipeline progress and cash runway accompanied a wider year-over-year net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings events showed mostly positive 24-hour reactions, with one negative reaction.
Key Terms
osteogenesis imperfecta medical
annualized clinical fracture rate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026
Cash and cash equivalents of
LONDON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.
The Company is also updating its previous cash runway guidance. As of June 30, 2026, cash and cash equivalents were approximately
“The partnership with Sentynl Therapeutics which we announced earlier today marks a significant milestone for our alvelestat program and for the Company as a whole. We are now working together to refine the design of the global Phase 3 study for our potential first-in-class oral therapy for AATD-LD and look forward to a continued close collaboration during the short option period. Assuming exercise of the license option by Sentynl, we plan to initiate the Phase 3 trial in early 2027,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. “Additionally, alongside our partner Ultragenyx, we have had initial regulatory interactions on setrusumab with the FDA and the MHRA and we expect to be in a position to provide an update on the potential path forward by the end of this year. We finished the quarter with approximately
Second Quarter 2026 Highlights, Recent Developments, and Anticipated Milestones
Setrusumab (UX143)
- The Orbit and the Cosmic Phase 3 studies did not achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate, however, both achieved high statistical significance against the key secondary endpoint of improvement in bone mineral density, as well as reductions in vertebral fractures and improvements in patient reported outcomes (PROs) associated with disease severity, pain / discomfort and daily activities, with these PRO improvements achieving statistical significance in the Orbit study. Setrusumab also achieved meaningful reductions in fractures in certain bones and in patients with higher fracture frequencies. Both studies demonstrated a safety profile consistent with that observed in previous trials.
- Mereo and its partner, Ultragenyx Pharmaceutical, Inc. (Ultragenyx), are engaged with regulatory agencies to determine a potential path forward for setrusumab in pediatric OI patients and, to-date, have held discussions with the regulators in the U.S. and the U.K. The FDA indicated openness to considering alternative approaches to fracture analysis, with additional conversations needed to further define what additional clinical data would be needed to support a potential BLA. In recent communications with the MHRA, they encouraged further dialogue on any future development proposal, and we plan to have further interactions following the FDA discussions.
Alvelestat (MPH-966)
- Mereo recently announced an option and license agreement with Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences Limited. Sentynl has the right to acquire a license for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
- Sentynl is a California-based, commercial-stage biopharmaceutical company with three currently approved products for rare diseases.
- Under the agreement, the companies will collaborate to refine the design of the planned global Phase 3 trial of alvelestat and to advance the manufacturing during the short option period.
- Mereo will receive a non-refundable option fee and, on option exercise, would also be eligible to receive
$40 million in upfront and R&D payments, up to$435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. - Mereo will lead the global Phase 3 study and regulatory interactions until study completion and will retain rest-of-world commercial rights for alvelestat.
- On exercise of the option by Sentynl, the agreement provides funding for the global Phase 3 study, which could be initiated early in 2027.
- Mereo will receive a non-refundable option fee and, on option exercise, would also be eligible to receive
Vantictumab (OMP18R5)
- āshibio, Inc. (āshibio), Mereo’s development and commercial partner for vantictumab, is continuing to advance toward initiation of a Phase 2 clinical trial in autosomal dominant osteopetrosis Type 2 (ADO2).
- āshibio is responsible for the global clinical development of vantictumab. Mereo has retained European commercial rights to the product, with āshibio holding commercial rights for the rest of the world.
Second Quarter 2026 Financial Results
Total research and development (“R&D”) expenses decreased by
General and administrative (“G&A”) expenses decreased by
Net loss for the second quarter of 2026 was
As of June 30, 2026, the Company had cash and cash equivalents of
Total ordinary shares issued as of June 30, 2026 were 798,093,044. Total ADS equivalents as of June 30, 2026 were 159,618,608, with each ADS representing five ordinary shares of the Company.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights to commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with āshibio, Inc., for vantictumab in ADO2. āshibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.
Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company’s reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company’s dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company’s dependence on its key executives; and the Company’s ability to maintain compliance with Nasdaq continued listing requirements.
You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook,” “will,” “continue” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.
| Mereo BioPharma Contacts: | ||
| Mereo | +44 (0)333 023 7300 | |
| Denise Scots-Knight, Chief Executive Officer | ||
| Christine Fox, Chief Financial Officer | ||
| Burns McClellan (Investor Relations Adviser to Mereo) | +01 646 930 4406 | |
| Lee Roth | ||
| Investors | investors@mereobiopharma.com | |
| MEREO BIOPHARMA GROUP PLC CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 30,118 | $ | 40,992 | ||||
| Prepaid expenses and other current assets | 1,600 | 2,531 | ||||||
| Research and development incentives receivables | 1,683 | 1,497 | ||||||
| Total current assets | 33,401 | 45,020 | ||||||
| Property and equipment, net | 54 | 137 | ||||||
| Operating lease right-of-use assets, net | 1,003 | 244 | ||||||
| Intangible assets, net | 256 | 516 | ||||||
| Total assets | $ | 34,714 | $ | 45,917 | ||||
| Liabilities | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,121 | $ | 1,333 | ||||
| Accrued expenses | 2,455 | 2,026 | ||||||
| Operating lease liabilities – current | 1,030 | 202 | ||||||
| Other current liabilities | 1,071 | 741 | ||||||
| Total current liabilities | 5,677 | 4,302 | ||||||
| Warrant liabilities – non-current | 15 | 38 | ||||||
| Other non-current liabilities | 370 | 661 | ||||||
| Total liabilities | $ | 6,062 | $ | 5,001 | ||||
| Shareholders’ Equity | ||||||||
| Ordinary shares, par value | $ | 3,145 | $ | 3,135 | ||||
| Additional paid-in capital | 552,335 | 549,622 | ||||||
| Accumulated deficit | (514,543 | ) | (501,018 | ) | ||||
| Accumulated other comprehensive loss | (12,285 | ) | (10,823 | ) | ||||
| Total shareholders’ equity | $ | 28,652 | $ | 40,916 | ||||
| Total liabilities and shareholders’ equity | $ | 34,714 | $ | 45,917 | ||||
| MEREO BIOPHARMA GROUP PLC CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | — | $ | 500 | $ | — | $ | 500 | ||||||||
| Operating expenses | ||||||||||||||||
| Cost of revenue | — | (132 | ) | — | (132 | ) | ||||||||||
| Research and development | (1,808 | ) | (5,373 | ) | (6,555 | ) | (9,303 | ) | ||||||||
| General and administrative | (5,222 | ) | (5,494 | ) | (9,241 | ) | (12,766 | ) | ||||||||
| Loss from operations | (7,030 | ) | (10,499 | ) | (15,796 | ) | (21,701 | ) | ||||||||
| Other income/(expenses) | ||||||||||||||||
| Interest income | 278 | 589 | 605 | 1,248 | ||||||||||||
| Interest expense | (16 | ) | (24 | ) | (37 | ) | (204 | ) | ||||||||
| Changes in the fair value of warrants | 6 | (101 | ) | 23 | 315 | |||||||||||
| Foreign currency transaction (loss)/gain, net | (362 | ) | (5,326 | ) | 1,267 | (8,091 | ) | |||||||||
| Benefit from research and development tax credit | 119 | 745 | 214 | 930 | ||||||||||||
| Net loss before income tax | (7,005 | ) | (14,616 | ) | (13,724 | ) | (27,503 | ) | ||||||||
| Income tax benefit | — | — | — | — | ||||||||||||
| Net loss | $ | (7,005 | ) | $ | (14,616 | ) | $ | (13,724 | ) | $ | (27,503 | ) | ||||
| Loss per share – basic and diluted | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.02 | ) | $ | (0.03 | ) | ||||
| Weighted average shares outstanding – basic and diluted | 803,562,708 | 799,435,329 | 802,688,993 | 794,022,295 | ||||||||||||
| Net loss | $ | (7,005 | ) | $ | (14,616 | ) | $ | (13,724 | ) | $ | (27,503 | ) | ||||
| Other comprehensive income/(loss) – Foreign currency translation adjustments, net of tax | 286 | 6,647 | (1,462 | ) | 10,206 | |||||||||||
| Total comprehensive loss | $ | (6,719 | ) | $ | (7,969 | ) | $ | (15,186 | ) | $ | (17,297 | ) | ||||
